Purpose. Mycoplasma hominis is considered among the causes of urogenital infections and shows increasing resistance to fluoroquinolones. However, data regarding the fluoroquinolone resistance mechanism of M. hominis in Southwest China are limited. This study aimed to investigate gene mutations of quinolone resistance-determining regions (QRDRs) of M. hominis isolated from clinical urogenital samples in a Chinese hospital.
INTRODUCTION
Mycoplasma hominis is commonly found in the urogenital tract of adults, and can cause many kinds of disease such as non-gonococcal urethritis (NGU), prostatitis, epididymitis, and infertility in males [1] [2] [3] , and vaginitis, cervicitis and pelvic inflammation in females, especially women of childbearing age [4] [5] [6] . Associations have also been reported with respiratory tract infections [7, 8] , mediastinitis [9] , skin and soft tissue infections [10] , central nervous system infections [11, 12] and adverse pregnancy outcomes [13, 14] , including miscarriage and pre-term birth, as well as with meningitis and bacteraemia in newborns.
Affiliated to the Mycoplasmataceae family and the Mollicutes class, M. hominis has a small genome size and limited biosynthetic functions [15] . Due to the lack of a cell wall, M.
hominis is naturally resistant to penicillin, vancomycin and all b-lactams. Further narrowing treatment options, M. hominis also has intrinsic resistance to sulfonamides, rifampin and 14-and 15-membered macrolides. The emergence of a 23S rRNA gene mutation in M. hominis could lead to loss of intrinsic resistance to erythromycin and azithromycin [16] . Fluoroquinolones are commonly used in the therapy of mycoplasma infections because of their broadspectrum antibacterial activity, good oral absorption and few side effects. Fluoroquinolones interact in mycoplasma and bacteria with type II topoisomerases, including DNA gyrase encoded by the gyrA and gyrB genes and topoisomerase IV encoded by the parC and parE genes [17] [18] [19] [20] .
Fluoroquinolone resistance in M. hominis has become progressively more serious as evidenced by repeated infections, delayed healing and irrational use of drugs [21, 22] . Bebear et al. determined the role of amino acid substitutions in DNA gyrase and topoisomerase IV from M. hominis in mediating fluoroquinolone resistance [23] [24] [25] . In recent years, studies on gene mutations of M. hominis resistant to fluoroquinolones have been published [19, [23] [24] [25] [26] [27] . However, gene mutation positions varied regionally and showed discrepancy between induced and clinical isolates. To our knowledge, data regarding fluoroquinolone resistance mechanisms of M. hominis in Southwest China are limited. The aim of this study was to analyse gene mutations in the quinolone resistance-determining regions (QRDRs) of M. hominis isolated from clinical urogenital samples in Chengdu, a city in Southwest China. Identification and verification of M. hominis by sequencing of 16S rRNA gene Clinical strains of fluoroquinolone-resistant M. hominis were screened using the AISN kit, and further identified by analysis of the DNA sequence of the 16S rRNA gene. The following primers were used for PCR amplification: BAK11w (5¢-AGTTTGATCATGGCTCAG-3¢) and BAK2 (5¢-GGACTACCAGGGTATCTAAT-3¢) [28] .
METHODS
Broth microdilution method for determination of fluoroquinolone MIC The MICs of ciprofloxacin (CIP), levofloxacin (LVX), moxifloxacin (MXF) and gatifloxacin (GAT) (JinZhang Science and Technology Co., Tianjin, China) were determined by the broth microdilution method. Each antibiotic was diluted in a series of concentrations using mycoplasma broth, and a volume of 100 µl fresh broth culture of M. hominis (10 4 -10 5 c.f.u. ml À1 ) was added. The inocula were sealed and incubated at 37 C for 48-72 h in a humidified cell culture incubator, with 5 % CO 2 . The MIC was defined as the lowest concentration of antibiotic that prevented a colour change in the medium from yellow to red, resulting from arginine hydrolysis. Results were determined according to Clinical and Laboratory Standards Institute (CLSI) guidelines [29] .
The standard strain of M. hominis, ATCC 23114, was used as quality control.
Amplification and sequencing of QRDRs of genes gyrA, gyrB, parC and parE We extracted DNA samples from M. hominis using a TIAN-GEN kit (Beijing, China), following the manufacturer's instructions, and the extracts were stored at À20 C for PCR amplification. Primers for QRDRs of the genes gyrA, gyrB, parC and parE were designed as previously described [23, 24] . PCR amplification was performed with the following parameters: 3 min at 98 C followed by 40 cycles of 10 s at 98 C, 10 s at 54 C and 10 s at 72 C; and a final extension of 5 min at 72 C. Positive products were sequenced. Gene mutations and amino acid substitutions of QRDRs were analysed by BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and DNAMAN software and compared to the reference strain, M. hominis ATCC23114 (GenBank accession number FP236530.1).
RESULTS
Fluoroquinolone resistance and molecular identification of M. hominis A total of 84 strains of M. hominis were isolated among 3652 outpatients admitted to Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, from October 2016 to September 2017. Resistance rates of M. hominis to CIP, LVX, MXF and GAT were 90.5 % (76/84), 85.7 % (72/84), 73.8 % (62/84) and 71.4 % (60/84), respectively. A total of 57 isolates were screened, of which 52 were resistant to fluoroquinolones. These resistant strains were identified and verified by 16S rRNA gene sequencing. The molecular identification results showed that all 52 strains were verified as M. hominis, in full agreement with the results of routine laboratory cultivation.
DNA mutations and amino acid substitutions of QRDRs
The 52 M. hominis strains, as verified by molecular identification of the 16S rRNA gene, were further amplified for the QRDRs of genes gyrA, gyrB, parC and parE. Five types of amino acid substitution in the QRDRs of the 52 strains, based on DNA sequencing, were identified (Table 1) : GyrA S153L (41 samples), ParC S91I (51 samples), ParC K144R (22 samples), ParC A154T (1 sample) and ParE A463S (2 samples). The mutation rates of GyrA S153L, ParC S91I, ParC K144R, ParC A154T and ParE A463S were 78.8 % (41/ 52), 98.1 % (51/52), 42.3 % (22/52), 1.9 % (1/52) and 3.8 % (2/52), respectively.
Relationship between amino acid substitutions and MIC change in fluoroquinolones Of the 52 strains of M. hominis, 41 harboured amino acid substitutions of GyrA S153L, resulting in the MIC of MXF and GAT increasing from 0.063 to 4-32 µg ml
À1
. The single ParC S91I mutation resulted in an increase in MIC of CIP from 1 to 4-8 µg ml
, and for LVX from 0.5 to 4-8 µg ml
. When ParC S91I was combined with GyrA S153L the MIC of CIP and LVX was further increased, to 128 µg ml
. The effect of amino acid substitutions on the MIC of ParC K144R was not obvious. The effect of ParE A463S on the two strains raised the MIC of LVX only marginally, from 64 to 128 µg ml
, while no change was found in the sample with ParC A154T compared to those lacking the mutation. No amino acid change was found in GyrB and the standard strain ATCC23114 (Table 2) .
DISCUSSION
In recent years, M. hominis has raised increased concerns because of its association with urogenital infections, infertility [1, 2] and adverse pregnancy outcomes [13, 14] .
Fluoroquinolones are commonly used for empirical therapy of mycoplasma infections but have recently exhibited increasing resistance rates. Due to different methodologies and different criteria for interpretation of antimicrobial susceptibility results, inconsistent fluoroquinolone resistance rates have been recorded [5, 6] . Krausse et al. investigated M. hominis isolated in Germany [30] , finding that the resistance rate of M. hominis to CIP was 7.9 % by agar dilution assay. Strains in Singapore [31] and M. hominis in Israel [32] also showed low resistance to fluoroquinolones, using the Etest method. Choi et al. recently found that resistance rates of ofloxacin (OFL) and CIP against M. hominis, isolated from asymptomatic individuals in Korea [33] , were respectively 17.7 and 35.3 %, using a Mycoplasma IST2 kit. In a recent Chinese report, CIP and OFL exhibited high resistance rates against M. hominis, also with the Ser, serine; Leu, leucine; Ile, isoleucine; Lys, lysine; Arg, arginine; Ala, alanine; Thr, threonine. Mycoplasma IST2 kit [34] . Because this is a commercial kit and not standardized, it is unreliable for the determination of resistance [35] . In our study, the broth microdilution method was used for antimicrobial susceptibility testing of fluoroquinolones, as recommended by CLSI. Our results show that the resistance rates of M. hominis to CIP, LVX, MXF and GAT were 90.5, 85.7, 73.8 and 71.4 %, respectively. Thus, it is necessary and important to clarify the resistance mechanism of fluoroquinolones in M. hominis to prevent the dissemination of resistant strains efficiently.
Of the 52 clinical samples of M. hominis, 41 harboured GyrA S153L amino acid variations, 51 harboured ParC S91I and 22 harboured ParC K144R. Amino acid substitutions of ParE A463S in two strains and ParC A154T in one sample were found for the first time. For M. hominis, GyrA position 153 corresponds to Escherichia coli coordinate 83; ParC positions 91, 144 and 154 correspond to E. coli coordinates 80, 133 and 143, respectively; and ParE position 463 corresponds to E. coli coordinate 457 [19, 26] . The amino acid substitutions GyrA Ser-83fileu, GyrA Glu-87fiLys, ParC Glu-84fiGly and ParC Ser-81fiPro (E. coli coordinates) in clinical isolates of M. hominis were previously reported [36] . In a Russian study [37] , ParC had an Asn substitute at position 91. GyrA S153L and ParC K144R substitutions were recently reported by Fürnkranz et al. [38] . These geographical differences in regard to mutation positions may have been the result of variations in antimicrobial exposure in different patient populations. In accordance with previous findings [25, 27] , several nucleotide mutations occurred in the gyrB gene but these were nonsense mutations and no amino acid change was found.
As shown in Table 2 , a total of 41 strains of M. hominis harbouring the GyrA S153L substitution were resistant to MXF and GAT, with MIC ranging from 4 to 32 µg ml
À1
. The single ParC S91I substitution resulted in an increase in MIC of four-to eight-fold against CIP, and eight-to 16-fold against LVX. Two strains that simultaneously carried three types of amino acid substitutions -GyrA S153L, ParC S91I and ParE A463S -exhibited high-level MIC against the fluoroquinolones tested (CIP, 128 µg ml
; LVX, 128 µg ml À1 ; MXF, 32 µg ml
; and GAT, 32 µg ml
). However, compared to those lacking a mutation, the change in ParE A463S resulted in only a small change in the MIC of LVX (one-fold), and no change was found in the sample harbouring ParC A154T. Clarification of the precise role of variations ParC A154T and ParE A463S requires the acquisition of further data.
It is known that different fluoroquinolones have different preferential targets [25, 27] . Our results showed that GyrA S153L substitutions were found in all strains resistant to MXF and GAT, but not in those sensitive to MXF and GAT. Gene mutations in ParC were detected in all strains resistant to CIP and LVX, irrespective of whether MXF and GAT were resistant. This suggests that MXF and GAT target primarily DNA gyrase but that CIP and LVX primarily target topoisomerase IV. The high-level resistance of fluoroquinolones is associated with gene mutations in both DNA gyrase and topoisomerase IV.
In conclusion, this study supplements current knowledge of the fluoroquinolone resistance mechanism of M. hominis in China. Our results suggest that resistance of M. hominis to fluoroquinolones is mainly related to amino acid substitutions caused by mutations in the QRDRs of the genes gyrA and parC, and that high-level resistance is associated with gene mutations in both DNA gyrase and topoisomerase IV. In regard to ongoing research, hybridization probes for common mutant positions will be designed for the rapid detection of fluoroquinolone resistance.
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